M

Monte Rosa Therapeutics Inc
NASDAQ:GLUE

Watchlist Manager
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Watchlist
Price: 5.99 USD -8.2% Market Closed
Market Cap: 368m USD

Monte Rosa Therapeutics Inc
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Monte Rosa Therapeutics Inc
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
M
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Change in Working Capital
$72.5m
CAGR 3-Years
157%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Change in Working Capital
-$1.9B
CAGR 3-Years
-19%
CAGR 5-Years
-7%
CAGR 10-Years
-20%
Gilead Sciences Inc
NASDAQ:GILD
Change in Working Capital
$7.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Change in Working Capital
-$612m
CAGR 3-Years
30%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Change in Working Capital
-$793.5m
CAGR 3-Years
-13%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Change in Working Capital
-$593.3m
CAGR 3-Years
28%
CAGR 5-Years
-7%
CAGR 10-Years
N/A

Monte Rosa Therapeutics Inc
Glance View

Market Cap
367.7m USD
Industry
Biotechnology

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company is headquartered in Boston, Massachusetts and currently employs 93 full-time employees. The company went IPO on 2021-06-24. The company is engaged in developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops a protein degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN), that enables it to identify protein targets and molecular glue degrader (MGD), product candidates that are designed to eliminate therapeutically relevant proteins. The company focuses on therapeutic targets backed by biological and genetic rationale discovering and developing novel precision medicines. Its lead product candidate is MRT-2359, which is an orally bioavailable degrader of the translation termination factor protein GSPT1 in development initially for use in the treatment of cancers. Its programs are focused on delivering therapies to targets that have been considered undruggable or inadequately drugged in biological pathways.

GLUE Intrinsic Value
3.83 USD
Overvaluation 36%
Intrinsic Value
Price
M

See Also

What is Monte Rosa Therapeutics Inc's Change in Working Capital?
Change in Working Capital
72.5m USD

Based on the financial report for Dec 31, 2023, Monte Rosa Therapeutics Inc's Change in Working Capital amounts to 72.5m USD.

What is Monte Rosa Therapeutics Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 3Y
157%

The average annual Change in Working Capital growth rates for Monte Rosa Therapeutics Inc have been 157% over the past three years .

Back to Top